Reducing TDP-43 aggregation does not prevent its cytotoxicity.

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• TAR DNA-binding protein 43 (TDP-43) is implicated in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).
• TDP-43 pathology involves its mislocalization and aggregation in neurons of affected patients.

Purpose of the Study:

• To identify regions of TDP-43 involved in its self-binding and aggregation.
• To design and test synthetic peptides for their ability to inhibit TDP-43 aggregation.

Main Methods:

• High-density peptide array analysis was used to map TDP-43 binding regions.
• Synthetic peptides were designed based on array results.
• Peptide efficacy was tested in HeLa cells overexpressing mutated or wild-type TDP-43, including under arsenite-induced stress.

Main Results:

• Two synthetic peptides effectively inhibited TDP-43 aggregate formation in a concentration-dependent manner.
• Despite reducing TDP-43 aggregation, these peptides did not prevent cell death in overexpression or arsenite-treated cells.
• Results indicate a dissociation between TDP-43 aggregation and cell death.

Conclusions:

• TDP-43 aggregation is associated with the cell death process in neurodegenerative conditions.
• TDP-43 aggregation may be a consequence rather than a direct cause of neuronal cell death in ALS and FTLD.